CaboCombo: A prospective international non-interventional study of first-line cabozantinib plus nivolumab for the treatment of patients with advanced renal cell carcinoma.

被引：0
|
作者：
Barthelemy, Philippe
Dutailly, Pascale
Qvick, Bryan
Perrot, Valerie
Verzoni, Elena
机构：
[1] Inst Cancerol Strasbourg Europe, Strasbourg, France
[2] Ipsen Pharma, Boulogne Billancourt, France
[3] Ipsen Pharma GmbH, Munich, Germany
[4] Ipsen, Boulogne Billancourt, France
[5] Fdn IRCCS Ist Nazl Tumori Milano, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS740
引用
收藏
页数：1
相关论文
共 50 条
  • [1] CaboCombo: a prospective, phase IV study of first-line cabozantinib plus nivolumab for advanced renal cell carcinoma
    Barthelemy, Philippe
    Dutailly, Pascale
    Qvick, Bryan
    Perrot, Valerie
    Verzoni, Elena
    FUTURE ONCOLOGY, 2024, 20 (13) : 811 - 819
  • [2] Cabozantinib and nivolumab as first-line treatment in advanced renal cell carcinoma
    Vitale, Maria Giuseppa
    Nasso, Cecilia
    Oltrecolli, Marco
    Baldessari, Cinzia
    Fanelli, Martina
    Dominici, Massimo
    Sabbatini, Roberto
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (11) : 1183 - 1192
  • [3] Non-interventional study on first-line therapy in advanced renal cell carcinoma
    Rexer, H.
    Merseburger, A.
    Doehn, C.
    UROLOGIE, 2023, 62 (02): : 220 - 221
  • [4] Non-interventional Study in advanced Renal Cell Carcinoma in First-line Therapy
    Rexer, H.
    Grimm, M. -O.
    Steiner, T.
    AKTUELLE UROLOGIE, 2020, 51 (06) : 528 - 529
  • [5] Advanced Renal Cell Carcinoma Cabozantinib plus Nivolumab: New First-Line Standard?
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (06) : 362 - 363
  • [6] COST EFFECTIVENESS OF CABOZANTINIB PLUS NIVOLUMAB AS FIRST-LINE TREATMENT FOR RENAL CELL CARCINOMA
    Marciniak, A.
    Gultyaev, D.
    Orbzut, G.
    Mollon, P.
    Wallace, J. F.
    VALUE IN HEALTH, 2022, 25 (07) : S300 - S301
  • [7] Non-interventional study of first-line therapy in advanced or metastatic renal cell carcinoma
    Rexer, Heidrun
    Wunderlich, Heiko
    Doehn, Christian
    AKTUELLE UROLOGIE, 2024, 55 (03)
  • [8] Bevacizumab plus IFN-alpha-2a in First-line Treatment of Patients With Advanced or Metastatic Renal Cell Carcinoma: A Prospective German Non-interventional Study
    Schultze-Seemann, Wolfgang
    Schulz, Holger
    Tschechne, Barbara
    Haeckl, Manuel
    ANTICANCER RESEARCH, 2019, 39 (02) : 875 - 882
  • [9] Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
    Hao, Wang
    Ye, Wang
    Li, Li
    Han, Zhou
    Shang, Lili
    Li, Liao
    Shen, Yike
    Ma, Aixia
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [10] Non-interventional Study in advanced Renal Cell Carcinoma in First-line therapy NIS NORA, a national prospective non-interventional Study for Patients with advanced/metastatic Renal Cell Carcinoma starting First-line therapy with Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy after previous Therapy (CA209-653) - AN 47/17 of AUO
    Rexer, H.
    Grimm, M. -O.
    Steiner, T.
    UROLOGE, 2020, 59 (05): : 649 - 650
12345